Cargando…

Current evidence on the use of anti-RAAS agents in congenital or acquired solitary kidney

Rational: The inhibition of renin–angiotensin–aldosterone system (RAAS) is a major strategy for slowing the progression of chronic kidney disease (CKD). The utility of anti-RAAS agents in patients with congenital or acquired solitary kidney is still controversial. Objective: A systematic literature...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simeoni, Mariadelina, Armeni, Annarita, Summaria, Chiara, Cerantonio, Annamaria, Fuiano, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	State-Of-The-Art Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446147/ https://www.ncbi.nlm.nih.gov/pubmed/28805480 http://dx.doi.org/10.1080/0886022X.2017.1361840

Ejemplares similares

Solitary pulmonary nodule imaging approaches and the role of optical fibre-based technologies
por: Fernandes, Susan, et al.
Publicado: (2021)

Secondary Hyperparathyroidism and Hypertension: An Intriguing Couple
por: Simeoni, Mariadelina, et al.
Publicado: (2020)

Acquired long QT syndrome in chronic kidney disease patients
por: Liu, Peng, et al.
Publicado: (2019)

Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options
por: Jankowski, Joachim, et al.
Publicado: (2021)

Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients
por: D’Onofrio, Giuseppina, et al.
Publicado: (2016)

The role of stents in the treatment of congenital heart disease: Current status and future perspectives
por: Peters, Bjoern, et al.
Publicado: (2009)

Correction to: An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD)
por: Simeoni, Mariadelina, et al.
Publicado: (2018)

An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD)
por: Simeoni, Mariadelina, et al.
Publicado: (2018)

Cystatin C, a Controversial Biomarker in Hypothyroid Patients under Levothyroxine Therapy: THYRenal, a Pilot Cohort Observational Study
por: Greco, Marta, et al.
Publicado: (2020)

Current stroke rehabilitation services and physiotherapy research in South Africa
por: Ntsiea, Mokgobadibe V.
Publicado: (2019)

Neutrophils in community-acquired pneumonia: parallels in dysfunction at the extremes of age
por: Grudzinska, Frances Susanna, et al.
Publicado: (2020)

Wasp venom-induced acute kidney injury: current progress and prospects
por: Yu, Fanglin, et al.
Publicado: (2023)

Percutaneous Transcatheter Closure of Congenital Ventricular Septal Defects
por: Song, Jinyoung
Publicado: (2023)

3D Printing is a Transformative Technology in Congenital Heart Disease
por: Anwar, Shafkat, et al.
Publicado: (2018)

Acute toxic kidney injury
por: Petejova, Nadezda, et al.
Publicado: (2019)

New agents approved for treatment of acute staphylococcal skin infections
por: Tatarkiewicz, Jan, et al.
Publicado: (2016)

Anti-interleukin-1 agents for pericarditis: a primer for cardiologists( )
por: Imazio, Massimo, et al.
Publicado: (2021)

Advance of autophagy in chronic kidney diseases
por: Deng, Xu, et al.
Publicado: (2017)

Hyperuricemia, the heart, and the kidneys – to treat or not to treat?
por: Petreski, Tadej, et al.
Publicado: (2020)

Estrogen and estrogen receptors in kidney diseases
por: Ma, Hao-Yang, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
por: Michos, Erin D., et al.
Publicado: (2023)

Targeting Vascular Calcification in Chronic Kidney Disease
por: Nelson, Adam J., et al.
Publicado: (2020)

Therapeutic apheresis in kidney diseases: an updated review
por: Chen, Yi-Yuan, et al.
Publicado: (2022)

The role of kidney injury biomarkers in COVID-19
por: Su, Lianjiu, et al.
Publicado: (2022)

Pioglitazone in diabetic kidney disease: forgotten but not gone
por: Papaetis, Georgios S.
Publicado: (2022)

Advances in imaging techniques to assess kidney fibrosis
por: Jiang, Buchun, et al.
Publicado: (2023)

Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging
por: Di Giovanni, Giuseppe, et al.
Publicado: (2022)

Advancing the science of management of arrhythmic disease in children and adult congenital heart disease patients within the last 25 years
por: Paul, Thomas, et al.
Publicado: (2023)

Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia
por: Giblett, Joel P., et al.
Publicado: (2016)

Lipids, blood pressure, kidney – what was new in 2011?
por: Barylski, Marcin, et al.
Publicado: (2011)

Biomarker for early renal microvascular and diabetic kidney diseases
por: Futrakul, Narisa, et al.
Publicado: (2017)

A long journey for acute kidney injury biomarkers
por: Oh, Dong-Jin
Publicado: (2020)

The research status and prospect of Periostin in chronic kidney disease
por: Jia, Yuan-yuan, et al.
Publicado: (2020)

Emergent processes in cognitive-emotional interactions
por: Pessoa, Luiz
Publicado: (2010)

Bipolar disorder
por: Goodwin, Frederick K., et al.
Publicado: (1999)

Depression in late life
por: Barry, D. Lebowitz
Publicado: (1999)

The treatment of schizophrenia: from premorbid manifestations to the first episode of psychosis
por: Davidson, Michael, et al.
Publicado: (2005)

Genetic bases for endophenotypes in psychiatric disorders
por: Berrettini, Wade H.
Publicado: (2005)

The pharmacological management of depression
por: Kupfer, David J.
Publicado: (2005)

Sleep and psychiatry
por: Abad, Vivien C., et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_t4nu4te9kbs84tu0501jnk7uld